Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multivesicular liposomes containing bleomycin for subcutaneous administration.

R Roy1, S Kim

  • 1UCSD Cancer Center, T-012, Department of Medicine, University of California, San Diego, La Jolla 92093.

Cancer Chemotherapy and Pharmacology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Denitrification and methane production in sediment of Hamilton Harbour (Canada).

Microbial ecology·2013
Same author

Parotid dosimetric changes correlate to weight loss during radical but not adjuvant head and neck radiotherapy: an exploratory analysis.

Clinical oncology (Royal College of Radiologists (Great Britain))·2013
Same author

An observational study of complications in chickenpox with special reference to unusual complications in an apex infectious disease hospital, Kolkata, India.

Journal of postgraduate medicine·2013
Same author

Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Oncogenesis·2013
Same author

Oesophageal Chemoradiotherapy in the UK--current practice and future directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2013
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Multivesicular liposomes enhance cancer treatment by creating a slow-release depot for bleomycin (BLM). This improves efficacy and reduces toxicity in preclinical models.

Area of Science:

  • Pharmacology
  • Biotechnology
  • Oncology

Background:

  • Optimal cancer treatment with cell-cycle-specific agents necessitates sustained cytotoxic drug levels.
  • Systemic administration of chemotherapy often faces challenges with drug delivery and toxicity.

Purpose of the Study:

  • To investigate the use of multivesicular liposomes as a slow-release depot for bleomycin (BLM) for subcutaneous (s.c.) administration.
  • To evaluate the therapeutic efficacy and toxicity profile of liposomal BLM compared to free BLM.

Main Methods:

  • Formulation of multivesicular liposomes encapsulating bleomycin.
  • Characterization of liposome size and drug leakage half-life in human plasma.
  • Assessment of the pharmacokinetic profile of s.c. liposomal bleomycin.

Related Experiment Videos

  • Evaluation of anti-tumor efficacy and survival in a B-16 melanoma mouse model.

    • Main Results:

    • Liposomes exhibited an average size of 19.1 microns.
    • The half-life of bleomycin leakage from liposomes in human plasma was 32.1 hours.
    • The half-life of s.c. liposomal bleomycin was 31.8 hours.
    • Encapsulation of bleomycin in multivesicular liposomes significantly improved the therapeutic index against s.c. B-16 melanoma in mice.

    Conclusions:

    • Multivesicular liposomes serve as an effective slow-release depot for bleomycin.
    • Liposomal bleomycin demonstrates enhanced anti-tumor efficacy, including tumor growth inhibition and increased lifespan.
    • Subcutaneous administration of liposomal bleomycin shows reduced toxicity compared to free bleomycin.